Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment designed for intraocular use. Ranibizumab binds to and inhibits the biologic activity of human vascular endothelial growth factor A (VEGF-A). Ranibizumab, which lacks an Fc region, has a molecular weight of approximately 48 kilodaltons and is produced by CHO expression system.
Ranibizumab is supplied at a concentration of 20 mg/mL as a sterile, colorless to pale yellow solution, which contains 10 mM histidine HCl, 10% α,α-trehalose dihydrate, 0.01% polysorbate 20, pH 5.5.
|
Name
|
Ranibizumab
|
|
CAS NO.
|
347396-82-1
|
|
Type
|
Fab fragment
|
|
Source
|
Humanized (from mouse)
|
|
Target
|
VEGF-A
|
|
Clone
|
Monoclone
|
|
Molecular Weight
|
48 kDa
|
|
Formula
|
C2158H3282N562O681S12
|
|
Antibody Form
|
Purified immunoglobulin
|
|
Physical Form
|
Solution
|
|
Grade Standard
|
Medicine Grade
|
|
Place of Origin
|
China(Mainland)
|
|
Storage
|
-70±15℃ for long-term storage, 2-8℃ for short-term storage, away from light.
|
bio-equip.cn
Shanghai Topwell Pharma Co., Ltd. is specialized in research, development, custom manufacturing and sales of Pharmaceutical Intermediates, APIs, Pharmaceutical Excipients, Health & Nutritional Ingredients, Polypeptides and Antibodies, etc..
Topwell has a professional R&D team. We have built close cooperative relationships with many research institutes and universities in China. In addition, we have very close cooperation relationships with many Chinese pharmaceutical factories.
Topwell aims to become a global leader in pharmaceutical & chemical industry.
中文
